These mutations in FGFR3 lead to both increased proliferation and survival of bladder cells, making this protein not only a potent oncogenic driver in bladder cancer but also a predictive biomarker of response to FGFR3 small molecule inhibitors (5, 6). This evidence concerns the gene FGFR3 and urinary bladder carcinoma.